The effectiveness of the current lipid-lowering therapy for refractory dyslipidaemia in patients with coronary artery disease: the price of ‘the lower, the better’- results of a survey by Japanese cardiologists
In the clinical setting in Japan, cardiologists prescribe ezetimibe to patients with dyslipidemia-complicated coronary artery disease (DL-CAD) who are difficult to manage even with the maximum tolerated dose of statins. If the combination of statins and ezetimibe fails to achieve target LDL-C levels, they shift their strategy to interventions targeting high triglycerides and polyunsaturated fatty acids, Satoru Hashimoto and colleagues, TCROSS Co., Ltd. and the Graduate School of Strategic Management at Chuo University, Japan, reported in the online edition of Expert Opinion on Pharmacotherapy.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations
